Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Fate Therapeutics (FATE)

Fate Therapeutics (FATE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 235,761
  • Shares Outstanding, K 113,894
  • Annual Sales, $ 63,530 K
  • Annual Income, $ -160,930 K
  • EBIT $ -197 M
  • EBITDA $ -183 M
  • 60-Month Beta 1.88
  • Price/Sales 3.98
  • Price/Cash Flow N/A
  • Price/Book 0.70

Options Overview Details

View History
  • Implied Volatility 236.44% ( +52.20%)
  • Historical Volatility 92.62%
  • IV Percentile 91%
  • IV Rank 48.36%
  • IV High 476.71% on 11/15/24
  • IV Low 11.45% on 09/16/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 204
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 4,024
  • Open Int (30-Day) 2,353

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.44
  • Number of Estimates 9
  • High Estimate -0.39
  • Low Estimate -0.48
  • Prior Year -0.45
  • Growth Rate Est. (year over year) +2.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.96 +9.95%
on 11/15/24
3.50 -38.43%
on 11/18/24
-1.04 (-32.45%)
since 10/22/24
3-Month
1.96 +9.95%
on 11/15/24
4.20 -48.69%
on 09/19/24
-1.62 (-42.84%)
since 08/22/24
52-Week
1.96 +9.95%
on 11/15/24
8.83 -75.59%
on 03/07/24
-0.24 (-9.83%)
since 11/22/23

Most Recent Stories

More News
FATE Presents Encourgaing Data From Lupus Study, Stock Gains

Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in its early-stage study on experimental pipeline candidate  FT819.Data showed...

IMCR : 32.73 (+1.90%)
CSTL : 29.01 (+0.45%)
FATE : 2.16 (+4.35%)
SPRO : 1.1500 (-3.36%)
Fate Therapeutics Reports Successful Clinical Remission in First Patient Treated with FT819 for Lupus Nephritis

A lupus nephritis patient achieved clinical remission after FT819 treatment, showing promising safety and immune reset outcomes. Quiver AI SummaryFate Therapeutics, Inc. announced promising results from...

FATE : 2.16 (+4.35%)
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

FATE : 2.16 (+4.35%)
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence

FATE : 2.16 (+4.35%)
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus

Fate Therapeutics FATE reported a loss of 40 cents per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 42 cents. The company reported a loss of 46 cents per...

IMCR : 32.73 (+1.90%)
CSTL : 29.01 (+0.45%)
ANIP : 56.59 (+1.31%)
FATE : 2.16 (+4.35%)
Fate Therapeutics: Q3 Earnings Snapshot

Fate Therapeutics: Q3 Earnings Snapshot

FATE : 2.16 (+4.35%)
Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

FATE : 2.16 (+4.35%)
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

FATE : 2.16 (+4.35%)
Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

FATE : 2.16 (+4.35%)
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

FATE : 2.16 (+4.35%)

Business Summary

Fate Therapeutics is a clinical-stage biopharmaceutical company, which is focused on the development of programmed cellular immunotherapies for cancer and immune disorders.' The company uses various therapeutic approaches for cell programming to develop cell therapies. The company programs cells of the...

See More

Key Turning Points

3rd Resistance Point 2.50
2nd Resistance Point 2.39
1st Resistance Point 2.23
Last Price 2.16
1st Support Level 1.96
2nd Support Level 1.85
3rd Support Level 1.69

See More

52-Week High 8.83
Fibonacci 61.8% 6.21
Fibonacci 50% 5.39
Fibonacci 38.2% 4.58
Last Price 2.16
52-Week Low 1.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar